Tolmar

Executive Summary

Tolmar is a privately held U.S. pharmaceutical company that specializes in the development and commercialization of long-acting injectable treatments for urology, oncology, and endocrinology. Founded in 2002 and headquartered in Buffalo Grove, Illinois, the company manages the full product lifecycle from R&D to commercialization, with a mission to address unmet medical needs through a patient-first approach. Tolmar's focus on complex, long-acting formulations positions it as a niche player in high-value therapeutic areas, leveraging its expertise to improve patient and healthcare provider experiences. While the company operates without significant public financial disclosure, its proprietary pipeline and vertically integrated business model suggest a stable, growth-oriented trajectory.

Upcoming Catalysts (preview)

• Q4 2026Potential FDA approval of new long-acting injectable for urology or oncology60% success
• Q1 2027Strategic partnership or licensing deal with a major pharmaceutical company50% success
• TBDPositive Phase 2/3 clinical trial readout for a pipeline candidate70% success